Drug Trial Radar · NCT01654146
ICON8: Weekly Chemotherapy in Ovarian Cancer
Last checked: Nov 20, 2026Latest source record: Jul 31, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,485
Planned (sponsor's estimate)
Start
Jun 2011
Primary completion
Jun 2017
Sponsor
- Lead sponsor
- Medical Research CouncilGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Cancer Research UK
- First posted
- Jul 31, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if weekly chemotherapy (i.e. giving paclitaxel or carboplatin at a lower dose every week) is more effective than standard chemotherapy (paclitaxel and carboplatin given once every three weeks over 18 weeks) in treating ovarian cancer. The investigators also want to see if weekly chemotherapy causes more or fewer side-effects than standard chemotherapy.
Conditions
- Ovarian Cancer
Interventions
CarboplatinDrug
AUC5 by intravenous infusion over 30-60 minutes
CarboplatinDrug
AUC2 by intravenous infusion over 30-60 minutes
PaclitaxelDrug
175mg/m2 by intravenous infusion over 3 hours
PaclitaxelDrug
80mg/m2 by intravenous infusion over 1 hour
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: Feasibility assessed as the number of cycles and dose intensity of protocol treatment delivered per patient.Time frame: 6 months after the 50th patient has been randomised to each arm and 6 months after the 50th patient with a plan to undergo delayed primary surgery has been randomised to each arm
- Stage 1: Safety assessed as the rate of any ≥ grade 3 toxicity experienced per patient.Time frame: 6 months after the 50th patient has been randomised to each arm and 6 months after the 50th patient with a plan to undergo delayed primary surgery has been randomised to each arm
- Stage 2: Progression Free Survival rate at 9 months after randomisationTime frame: 9 months after first 62 patients randomised per arm
- Stage 3: Progression Free SurvivalTime frame: PFS expected 1 year after last patient is randomised. OS expected 3 years after last patient is randomised.
- Stage 3: Overall SurvivalTime frame: PFS expected 1 year after last patient is randomised. OS expected 3 years after last patient is randomised.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical Research Council Clinical Trials Unit
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.